This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Latres, E. Articles by Cordon-Cardo, C. Search for Related Content PubMed PubMed Citation Articles by Latres, E. Articles by Cordon-Cardo, C.

American Journal of Pathology, Vol 145, 345-355, Copyright © 1994 by American Society for Investigative Pathology

REGULAR ARTICLES

Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas

E Latres, M Drobnjak, D Pollack, MR Oliva, M Ramos, M Karpeh, JM Woodruff and C Cordon-Cardo
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.

This study was designed to determine the frequency of structural genetic abnormalities of chromosome 17 and the incidence of TP53 mutations as they relate to the biological behavior of adult soft tissue sarcomas. We analyzed a group of 73 soft tissue sarcomas of adults that were clinically and pathologically well characterized using molecular genetic techniques and expression studies. We then correlated genotype and phenotype with pathological parameters. Overall, allelic loss of 17p and 17q was identified in 53 and 29% of informative cases, respectively. p53 nuclear overexpression was detected in 34% of the tumors analyzed. We observed an association between 17p deletions and tumor presentation being more frequent in recurrent and metastatic tumors than primary lesion. p53 nuclear overexpression was associated with tumor grade, size, and more frequently detected in metastatic than primary sarcomas. The 11 intragenic mutations characterized included 10 cases of single base substitution and one single base deletion; 8 were of the missense type and 3 were nonsense. It is concluded that 17p deletions and TP53 mutations are common events in adult soft tissue sarcomas and that due to the trends observed with the cohort of patients analyzed they may become prognostic markers for patients affected with these tumors.

This article has been cited by other articles:

				J. N. Cormier and R. E. Pollock Soft Tissue Sarcomas CA Cancer J Clin, March 1, 2004; 54(2): 94 - 109. [Abstract] [Full Text] [PDF]

				T. Adachi, Y. Oda, A. Sakamoto, T. Saito, S. Tamiya, K. Masuda, and M. Tsuneyoshi Immunoreactivity of p53, mdm2, and p21WAFL in Dedifferentiated Liposarcoma: Special Emphasis on the Distinct Immunophenotype of the Well-differentiated Component International Journal of Surgical Pathology, April 1, 2001; 9(2): 99 - 109. [Abstract] [PDF]

				A. L. Folpe, R. H. Lyles, J. T. Sprouse, E. U. Conrad III, and J. F. Eary (F-18) Fluorodeoxyglucose Positron Emission Tomography as a Predictor of Pathologic Grade and Other Prognostic Variables in Bone and Soft Tissue Sarcoma Clin. Cancer Res., April 1, 2000; 6(4): 1279 - 1287. [Abstract] [Full Text]

				L. Jialiang, Y. Guanghua, and L. Gandi Observations on Tumor and Metastatic Suppressor Gene Status in Human Fibrous Neoplasms with Particular Emphasis on p53 and nm23 International Journal of Surgical Pathology, October 1, 1996; 4(2): 87 - 92. [Abstract] [PDF]